This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutCurrent Treatment LandscapeMechanism Of Action (MOA)DosingDosingRecommended dosing scheduleEfficacy & Safety ProfileEfficacy & SafetyAcute Clinical EfficacyPrevention Clinical EfficacySafety and Tolerability ProfileSupporting ResourcesSupport & ResourcesMaterialsVideosOnline Learning

Click here for Vydura® (rimegepant) Prescribing Information for Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page.

Mechanism of Action (MOA)VYDURA is one of the targeted migraine therapies1-4
  • Calcitonin gene-related peptide (CGRP) is a pain-signalling neuropeptide that plays a causative role
    in migraine2,3
     
  • VYDURA selectively binds with high affinity to the human CGRP receptor and antagonises CGRP receptor function.1
     
  • The relationship between pharmacodynamic activity and the mechanism(s) by which VYDURA exerts its clinical effects is unknown.1
     
  • Currently, there are no data suggesting that chronic blockage of the CGRP receptor can induce medication overuse headache (MOH), although long-term effects of CGRP receptor blocking agents should be studied.6
     
  • However, overuse of any type of medicinal products for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained, and treatment should be discontinued.1
     
  • The diagnosis of MOH should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of medicinal products for acute headache.1
For more details, please refer to the SmPC.

CGRP, calcitonin gene-related peptide; MOH, medication overuse headache
Current Treatment Landscape
Understand why there is a need for new treatments for migraines
Current Treatment Landscape
Loading
Recommended dosing schedule
Learn about VYDURA’s recommended dosing schedule, advice for patients and coadministration of medicines
Recommended dosing schedule
LoadingCGRP receptor antagonists work by:

Adapted from Durham 20044

Adapted from Durham 20044

 Vydura Mechanism of ActionAn animated explanation of Vydura's mechanism of action. Go to videoLoadingExplore morePrevious page

Understand why there is a need for new treatments for migraines
 
Current treatment Landscape
 Next page

Learn about VYDURA’s recommended dosing schedule, advice for patients and coadministration of medicine
Recommended dosing schedule
 Register for PfizerProSign up to recieve tailored content specific to your interests Register here
CGRP, calcitonin gene-related peptide; MOH, medication overuse headache

References:
  1. Vydura (rimegepant) Summary of Product Characteristics for Great Britain; Vydura (rimegepant) Summary of Product Characteristics for Northern Ireland.
  2. Burch R. Continuum (Minneap Minn) 2021; 27:613–632.
  3. Russel FA et al. Physiol Rev 2014;  94:1099–1142.
  4. Durham PL. N Engl J Med 2004; 350:1073–1075.
  5. Scott LJ. Drugs 2020; 80:741–746.
  6. van Hoogstraten WS, MaassenVanDenBrink A. J Headache Pain 2019; 20:54.
PP-NNT-GBR-0066. December 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​